AIMS: The objective of this study was to investigate whether baseline receptor activator for nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) serum (s) levels can predict the therapeutic response to TNF antagonists (a-TNF). METHODS: We studied 75 rheumatoid arthritis patients (81% female) with a longstanding refractory disease. The variables of disease activity, physical function and sRANKL and sOPG levels were determined before and after both 12-14 and 28-30 weeks of a-TNF therapy (65 adalimumab, 10 infliximab). Remission was defined by a 28 joint count disease activity score (DAS28) </=2.6 and clinical response by a reduction in DAS28>/=1.2 at both 3- and 7-month follow-up visits. RESULTS: In most patients, disease activity was severe, as reflected by a baseline DAS28 score of 5.9+/-1 (mean+/-SD), an HAQ of 1.6 (1.1 to 2.1) (median (interquartile range (IQR))) and a CRP 15 mg/l (IQR: 9 to 24). The sRANKL levels and RANKL/OPG ratio in patients that achieved remission were significantly lower at baseline than in the remaining patients at both 3 and 7 months of follow-up. The sOPG levels correlated with the HAQ and the physician's disease assessment and diminished significantly after a-TNF treatment. However, no significant association was detected between the therapeutic response profile and sOPG levels. CONCLUSIONS: These data suggest that in patients receiving a-TNF treatment, lower serum levels of RANKL and RANKL/OPG ratio may serve to predict remission.
AIMS: The objective of this study was to investigate whether baseline receptor activator for nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) serum (s) levels can predict the therapeutic response to TNF antagonists (a-TNF). METHODS: We studied 75 rheumatoid arthritispatients (81% female) with a longstanding refractory disease. The variables of disease activity, physical function and sRANKL and sOPG levels were determined before and after both 12-14 and 28-30 weeks of a-TNF therapy (65 adalimumab, 10 infliximab). Remission was defined by a 28 joint count disease activity score (DAS28) </=2.6 and clinical response by a reduction in DAS28>/=1.2 at both 3- and 7-month follow-up visits. RESULTS: In most patients, disease activity was severe, as reflected by a baseline DAS28 score of 5.9+/-1 (mean+/-SD), an HAQ of 1.6 (1.1 to 2.1) (median (interquartile range (IQR))) and a CRP 15 mg/l (IQR: 9 to 24). The sRANKL levels and RANKL/OPG ratio in patients that achieved remission were significantly lower at baseline than in the remaining patients at both 3 and 7 months of follow-up. The sOPG levels correlated with the HAQ and the physician's disease assessment and diminished significantly after a-TNF treatment. However, no significant association was detected between the therapeutic response profile and sOPG levels. CONCLUSIONS: These data suggest that in patients receiving a-TNF treatment, lower serum levels of RANKL and RANKL/OPG ratio may serve to predict remission.
Authors: F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra Journal: Arthritis Rheum Date: 1988-03
Authors: T N Crotti; M D Smith; H Weedon; M J Ahern; D M Findlay; M Kraan; P P Tak; D R Haynes Journal: Ann Rheum Dis Date: 2002-12 Impact factor: 19.103
Authors: Anca Irinel Catrina; Erik af Klint; Sofia Ernestam; Sergiu-Bogdan Catrina; Dimitrios Makrygiannakis; Ileana Ruxandra Botusan; Lars Klareskog; Ann-Kristin Ulfgren Journal: Arthritis Rheum Date: 2006-01
Authors: Maria Ziolkowska; Mariola Kurowska; Anna Radzikowska; Grazyna Luszczykiewicz; Piotr Wiland; Wojciech Dziewczopolski; Anna Filipowicz-Sosnowska; Jacek Pazdur; Jacek Szechinski; Jacek Kowalczewski; Maria Rell-Bakalarska; Wlodzimierz Maslinski Journal: Arthritis Rheum Date: 2002-07
Authors: C A F Zerbini; P Clark; L Mendez-Sanchez; R M R Pereira; O D Messina; C R Uña; J D Adachi; W F Lems; C Cooper; N E Lane Journal: Osteoporos Int Date: 2016-10-31 Impact factor: 4.507
Authors: Harjit P Bhattoa; Zoltán Szekanecz; Boglárka Soós; Ágnes Szentpétery; Hennie G Raterman; Willem F Lems Journal: Nat Rev Rheumatol Date: 2022-03-10 Impact factor: 20.543
Authors: Marije F Bakker; Suzanne M M Verstappen; Paco M J Welsing; Johannes W G Jacobs; Zalima N Jahangier; Maaike J van der Veen; Johannes W J Bijlsma; Floris P J G Lafeber Journal: Arthritis Res Ther Date: 2011-05-08 Impact factor: 5.156
Authors: Raimund H M Preidl; Tobias Ebker; Martin Raithel; Falk Wehrhan; Friedrich W Neukam; Philipp Stockmann Journal: BMC Gastroenterol Date: 2014-01-08 Impact factor: 3.067